Susan Chi, Md

This study is testing a combination of three drugs—tazemetostat, nivolumab, and ipilimumab—as a potential treatment for children and young adults with rare, aggressive cancers caused by missing specific proteins (INI1 or SMARCA4). The first part aims to find the safest dose, and …